Pioneering diagnostics
E.g., 25/02/2018
E.g., 25/02/2018

Lyme disease diagnostic tests

17 October, 2016

Like other laboratories, bioMérieux has been summoned to appear before the Tribunal de Grande Instance de Paris by 45 patients to obtain compensations linked to anxiety allegedly “generated by a lack of reliability of serodiagnostic tests” for Lyme disease.
 ...

FilmArray® Respiratory Panel EZ is CLIA waived by the FDA

11 October, 2016

bioMérieux, a world leader in the field of in vitro diagnostics, announced that BioFire Diagnostics, LLC, its molecular biology affiliate, received U.S. Food and Drug Administration (FDA) 510(k) clearance and Clinical Laboratory Improvement Amendments (CLIA) waiver for the FilmArray...

BIOASTER, bioMérieux, ESPCI, GSK, Hospices Civils de Lyon and Sanofi join forces against sepsis 

10 October, 2016

BIOASTER, the French accelerator of microbiology technology innovation, bioMérieux, ESPCI (College of Physics and Industrial Chemistry of the city of Paris), GSK, the Hospices Civils de Lyon (HCL) and Sanofi announce that they are combining their expertise to fight against sepsis within REALISM...

bioMérieux introduces EviSight™ Compact, a new automated diagnostic solution for microbial detection in pharmaceutical production

06 October, 2016

bioMérieux, a world leader in the field of industrial microbiological control, announces the launch of EviSight™ Compact, an intelligent incubator system providing real time culture media reading. For use in pharmaceutical industry R&D and production settings, EviSight™...

bioMérieux – First-Half 2016 Results

31 August, 2016

  • Strong growth in sales, up 10.9% at constant exchange rates and scope of consolidation:
    • €1,001 million in sales
    • Up 7.2% as reported
  • Sharp 22% improvement in contributive operating income before...

bioMérieux – Second-Quarter 2016 Business Review

18 July, 2016

  • Strong growth in sales, up 10.9%, at constant exchange rates and scope of consolidation in the first half of 2016:
  •   Sales reached €1,001 million
  •   Up 7...

bioMérieux enlarges its pathogen identification capability on VITEK® MS

With a database of more than 15,000 strains VITEK® MS improves clinical decision-making for infectious diseases

06 July, 2016

bioMérieux, a world leader in the field of in vitro diagnostics, announced the launch of the first CE-marked database and reagent kits for the identification of mycobacteria, Nocardia, and moulds in a MALDI-TOF1 Mass Spectrometry System. This innovative...

bioMerieux Receives FDA Clearance for Expanded Use of VIDAS® B•R•A•H•M•S PCT™ Test for Managing Sepsis Patients with elevated risk of mortality

Tracking PCT – a biomarker for bacterial infections – over time provides strong indication of likely mortality, enabling physicians to personalize care for high-risk patients

01 July, 2016

bioMérieux, a world leader in the field of in vitro diagnostics, today announced that it has received 510(k) clearance from the U.S....

bioMérieux acquires Hyglos and expands its offering to the detection of endotoxins in pharmaceutical products

   

01 June, 2016

bioMérieux, a global player in in vitro diagnostics and world leader in industrial microbiological control, announces the acquisition of Hyglos, a Bernried (Germany) - based company specializing in the detection of endotoxins. Founded...

bioMérieux and the Lyon Civil Hospitals strengthen their collaboration and expand their partnership to include Claude Bernard University Lyon 1 

Two joint research laboratories focused on a common goal: advancing medical research for the benefit of patients

31 May, 2016

bioMérieux, a world leader in the field of in vitro diagnostics, and the Lyon Civil Hospitals today inaugurated new joint research laboratory facilities located within the Edouard Herriot Hospital in Lyon, renewing their collaboration agreement for five years and expanded their...